Copyright: Published by Elsevier Ltd. Approximately 6·7 billion SARS-CoV-2 tests, including over 1·5 billion laboratory-based, 1·9 billion point-of-care (POC), and ...
QuidelOrtho Corporation is broadening its point-of-care diagnostic offerings with the launch of the QUICKVUE Influenza + SARS ...
Article subjects are automatically applied from the ACS Subject Taxonomy and describe the scientific concepts and themes of the article. Pune, a metropolitan city in western India, where this study ...
Azelastine demonstrated an increase in mean time to SARS-CoV-2 infection among infected patients, a reduction of the overall number of PCR-confirmed symptomatic infections, and a lower incidence of ...
In the intention-to-treat population, the incidence of polymerase chain reaction-confirmed SARS-CoV-2 infection was significantly lower in the azelastine group vs the placebo group. HealthDay News — ...
The polymerase chain reaction-confirmed SARS-CoV-2 infection rate was 2.2% with azelastine vs 6.7% with placebo. HealthDay News — Azelastine nasal spray is associated with a reduced risk for severe ...
Azelastine nasal spray is associated with a reduced risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. HealthDay News — Azelastine nasal spray is associated with a ...
The global pandemic may be over, but SARS-CoV-2 continues to infect people around the world. Indeed, the United States has recorded roughly 750 deaths from COVID-19 over the past month. Now, an siRNA ...
The trial, led by Professor Robert Bals, Director of the Department of Internal Medicine V at Saarland University Medical Center and Professor of Internal Medicine at Saarland University, divided the ...
Rapid Antigen Tests (Ag-RDTs) for the detection of SARS-CoV-2 is an important diagnostic tool for containing virus spread. However, their accuracy – the proportion of correct results (both true ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback